ASCO 2023: Final Prespecified Overall Survival Analysis of CLEAR: 4-Year Follow-up of Lenvatinib + Pembrolizumab vs Sunitinib in Patients with Advanced RCC
A real-world 1:1 propensity-matched study revealed unmarried status was independently associated with worse survival for patients with renal clear cell carcinoma
CLEAR Study: First-Line Lenvatinib Plus Pembrolizumab Maintains Advantage Over Sunitinib in Advanced RCC at Long-Term Follow-up
Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging | British Journal of Cancer
A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance) - eBioMedicine
A Novel Nomogram Predicting the Overall Survival of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Large Population-Based Investigation | SpringerLink
Figure 1 | Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression
Non-Small Cell Lung Cancer
Prognostic Value of Serum CA9 in Patients with Metastatic Clear Cell Renal Cell Carcinoma under Targeted Therapy | Anticancer Research
Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099) - ScienceDirect
Cancers | Free Full-Text | COL7A1 Expression Improves Prognosis Prediction for Patients with Clear Cell Renal Cell Carcinoma Atop of Stage
Kaplan–Meier curves showing recurrence-free survival and overall... | Download Scientific Diagram
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma | Anticancer Research
Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy - Clinical Genitourinary Cancer
ASCO 2022: Progression-Free Survival After Second Line of Therapy (PFS-2) for Metastatic Clear Cell RCC in Patients Treated With First-Line Immunotherapy Combinations
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
ASCO 2023: Final Prespecified Overall Survival Analysis of CLEAR: 4-Year Follow-up of Lenvatinib + Pembrolizumab vs Sunitinib in Patients with Advanced RCC
Oncotarget: Identification intermediate-risk | EurekAlert!
Kaplan–Meier curves depicting overall survival (OS; a, b) and... | Download Scientific Diagram
Six RNA binding proteins (RBPs) related prognostic model predicts overall survival for clear cell renal cell carcinoma and is associated with immune infiltration | Biomolecules and Biomedicine
Cancers | Free Full-Text | Evaluation of Survival, Recurrence Patterns and Adjuvant Therapy in Surgically Staged High-Grade Endometrial Cancer with Retroperitoneal Metastases
